Skip to main content

#160536

Anti-Cadherin 6 [2B6-D8]

Cat. #160536

Anti-Cadherin 6 [2B6-D8]

Cat. #: 160536

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: Cadherin-6

Class: Monoclonal

Application: IHC

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Jack A Schalken

Institute: Radboud University Medical Center (UMC)

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-Cadherin 6 [2B6-D8]
  • Alternate name: Cadherin 6, CDH6
  • Research fields: Cancer;Cell biology
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Host: Mouse
  • Application: IHC
  • Description: From Shimazui et al Clin Cancer Res. 1998 Oct;4(10):2419-24. "In many carcinomas, E-cadherin is considered to be a prognostic marker for patient survivals, and its decreased expression is associated with metastatic disease. Among renal cell carcinomas (RCCs), however, only 20% of tumors express E-cadherin, whereas a much higher percentage express other cadherins, e.g., N-cadherin and cadherin-6. Among these cadherins expressed in RCCs, cadherin-6 has been identified as a major cadherin in the renal proximal tubules and in the tumors themselves." The inventors of this reagent found that " These results suggest that cadherin-6 is a major cadherin playing an essential role in cell-cell adhesion in E-cadherin-absent RCC."
  • Immunogen: glutathione S-transferase (GST) fusion extracellular domain of human cadherin-6a
  • Myeloma used: Sp2/0-Ag14

Target Details

  • Target: Cadherin-6
  • Target background: From Shimazui et al Clin Cancer Res. 1998 Oct;4(10):2419-24. "In many carcinomas, E-cadherin is considered to be a prognostic marker for patient survivals, and its decreased expression is associated with metastatic disease. Among renal cell carcinomas (RCCs), however, only 20% of tumors express E-cadherin, whereas a much higher percentage express other cadherins, e.g., N-cadherin and cadherin-6. Among these cadherins expressed in RCCs, cadherin-6 has been identified as a major cadherin in the renal proximal tubules and in the tumors themselves." The inventors of this reagent found that " These results suggest that cadherin-6 is a major cadherin playing an essential role in cell-cell adhesion in E-cadherin-absent RCC."

Applications

  • Application: IHC

Handling

  • Format: Liquid
  • Unit size: 100 ug
  • Shipping conditions: Dry ice

References

  • Shimazui et al. 1998. Clin Cancer Res. 4(10):2419-24. PMID: 9796973.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.